硫化氢是新近发现的心肌保护性气体分子，可减轻心肌细胞的缺血再灌注损伤，改善移植心脏的功能，然而硫化氢本身的不稳定性限制了其在心脏移植保存液中的应用。本研究在前期工作基础上，旨在通过高分子合成方法制备冷触发相变凝胶，并包裹硫化氢控释纳米微粒，从而构建冷触发硫化氢控释纳米微粒。此微粒在常温下成凝胶状态稳定存在于保存液中，在低温（4℃）时呈液态，可以持续地释放硫化氢。此特性极大地简化了在心脏保存液中添加硫化氢供体的操作步骤，为发展一体式含硫化氢心脏保存液奠定基础。同时持续稳定的硫化氢释放更符合生理情况。在离体心脏模型中，通过代谢组学方法，本研究揭示了一条可能全新的硫化氢对缺血心脏的保护机制---通过ATGL/PPARα途径。项目成果对于深化硫化氢保护心肌的分子机制提供重要理论进展，为发展冷触发硫化氢控释纳米微粒在心脏保存液的应用提供重要的理论基础。本研究将为心脏移植患者的供心选择带来福音。

Hydrogen sulfide is a recently discovered cardioproctective gas molecule. It prevents cardiocytes from ischemia/reperfusion injury through multiple pathways, and then further improves the transplanted heart performance. However, the instability of hydrogen sulfide restricts its application in heart reserving solution. This study, based on our previous research, aims to construct cold-temperature-responsive nanoparticles for controlled hydrogen sulfide release. In this study, the hydrogen sulfide nanoparticles are embedded in cold-temperature-responsive hydrogel. When the temperature cools down from room temperature to a low temperature(4℃), the hydrogel exhibits a temperature-dependent gel-sol phase transition. The hydrogen sulfide nanoparticles are released with continuous, steady hydrogen sulfide release as well. Meanwhile the continuous and steady release rate of hydrogen sulfide is more consistent with physiological situations. In this study, we also try to investigate the mechanism of the cardioproctective effects by hydrogen sulfide under low temperature situation through metabonomic technique（ATGL/PPARα pathway）. If the hydrogen sulfide release system can be used successfully in heart reserve solution, it might bring a better and longer cardiac protective effect in the isolated heart model and heart transplantation animal model. The present study provides a new idea of heart reserve solution, and if successful, it brings more good news for heart transplant patients.